Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05186857 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Metabolome and Microbiome Impact on Acute GVHD in Recipients of Hematopoietic Transplant

Study acronym: AlloBolome
StatusActive, Not Recruiting
PhaseNot specified
Started2023-01-23
View on ClinicalTrials.gov ↗

Amendment history

2026-01-15
minor
Study Status, Contacts/Locations v4
Primary completion dateestimated 2024-12→confirmed 2025-12-15
Completion date2025-12→2026-12
Study sitesdetails revised at 8 of 9 sites
2024-03-15
notable
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v3
Trial statusRecruiting→Active, Not Recruiting
Primary completion date2025-04→2024-12
Completion date2027-04→2025-12
Enrollment targetestimated 120→confirmed 88
Study sitesdetails revised at 9 of 9 sites
2023-02-16
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2024-04→2025-04
Completion date2026-04→2027-04
Start dateestimated 2022-09-15→confirmed 2023-01-23
Study sitesdetails revised at 9 of 9 sites
2022-07-08
minor
Study Status, Contacts/Locations v1
Primary completion date2023-10→2024-04
Completion date2025-10→2026-04
Start date2022-03→2022-09-15
Study sites8→9
2021-12-23
minor
Original filing
Recent published data suggest that specific alterations in intestinal metabolome signature of hematopoietic stem cell transplant (allo-SCT) recipients might influence incidence and severity of acute graft versus host disease (aGVHD). Nevertheless, this possible relationship has not been undoubtedly established, pathophysiologic mechanisms have not been elucidated and possible clinical implications have not been studied. We hypothesized that in the early phase of allo-SCT, specific alterations in faecal metabolome occurred related to loss of intestinal microbiota diversity and disbalance of specific bacterial taxa, and that both alterations determine reduced survival of patients through increased incidence and severity of aGVHD. To test this hypothesis, a prospective multi-center cohort of allo-SCT recipients will had faecal and plasmatic samples collected at predetermined time-points pre\&post-allo-SCT, and clinical relevant variables will be prospectively recorded throughout two years posttransplant follow-up. Metabolomic and microbiome analysis will be done to answer objectives of the study. To additionally explore if differential evolving characteristics in the intestinal metabolome and microbiome of donor/recipient sibling pairs influence the incidence and severity of aGVHD, probability of malignancy relapse and early and late mortality an additional cohort of family donors of enrolled patients will also have faecal and plasmatic samples collected and analysed.
Trial Details
NCT Number NCT05186857
Lead Sponsor Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Collaborators: Instituto de Salud Carlos III
Conditions Graft-versus-host Disease
Enrollment 88 participants
Start Date 2023-01-23
Primary Completion 2025-12-15 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-16